APA (7th ed.) Citation

Swearingen, C., Yazici, Y., Tambiah, J. R. S., & Conaghan, P. G. (2024). POS1177 TREATMENT WITH LORECIVIVINT LEADS TO IMPROVED LONG-TERM PATIENT ACCEPTABLE SYMPTOM STATE (PASS) COMPARED TO PLACEBO: DATA FROM PHASE 3 EXTENSION TRIAL. Annals of the rheumatic diseases, 83(Suppl 1), 670-671. https://doi.org/10.1136/annrheumdis-2024-eular.5875

Chicago Style (17th ed.) Citation

Swearingen, C., Y. Yazici, J. R. S. Tambiah, and P. G. Conaghan. "POS1177 TREATMENT WITH LORECIVIVINT LEADS TO IMPROVED LONG-TERM PATIENT ACCEPTABLE SYMPTOM STATE (PASS) COMPARED TO PLACEBO: DATA FROM PHASE 3 EXTENSION TRIAL." Annals of the Rheumatic Diseases 83, no. Suppl 1 (2024): 670-671. https://doi.org/10.1136/annrheumdis-2024-eular.5875.

MLA (9th ed.) Citation

Swearingen, C., et al. "POS1177 TREATMENT WITH LORECIVIVINT LEADS TO IMPROVED LONG-TERM PATIENT ACCEPTABLE SYMPTOM STATE (PASS) COMPARED TO PLACEBO: DATA FROM PHASE 3 EXTENSION TRIAL." Annals of the Rheumatic Diseases, vol. 83, no. Suppl 1, 2024, pp. 670-671, https://doi.org/10.1136/annrheumdis-2024-eular.5875.